Evaluation of chromosome 1p/19q deletion by Fluorescence in Situ Hybridization (FISH) as prognostic factors in malignant glioma patients on treatment with alkylating chemotherapy

被引:2
作者
Pandith, Arshad A. [1 ,7 ]
Zahoor, Wani [1 ]
Manzoor, Usma [1 ]
Nisar, Syed [2 ]
Guru, Faisal R. [2 ]
Naikoo, Niyaz A. [3 ]
ul Aein, Qurat [1 ]
Baba, Shahid M. [1 ]
Bhat, Abdul R. [4 ]
Ganai, Farooq [5 ]
Shah, Parveen [6 ]
机构
[1] Sher I Kashmir Inst Med Sci SKIMS, Adv Ctr Human Genet, Srinagar, J&k, India
[2] Sher I Kashmir Inst Med Sci SKIMS, Dept Med Oncol, Srinagar, J&K, India
[3] Cluster Univ, Higher Educ Dept, Dept Biotechnol, Srinagar, J&K, India
[4] Sher I Kashmir Inst Med Sci SKIMS, Dept Neurosurg, Srinagar, India
[5] Sher I Kashmir Inst Med Sci SKIMS, Dept CVTS, Srinagar, J&K, India
[6] SKIMS, Dept Pathol, Srinagar, J&K, India
[7] Sher I Kashmir Inst Med Sci SKIMS, Adv Ctr Human Genet, Srinagar, Kashmir, India
关键词
Glioma; Chromosome; 1p/19q; Glioblastoma; Co-deletion; Astrocytoma; DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMAS; PHASE-III TRIAL; ADJUVANT PROCARBAZINE; ADULT GLIOMA; 1P; TUMORS; 19Q; TEMOZOLOMIDE; SURVIVAL; OLIGOASTROCYTOMAS;
D O I
10.1016/j.cancergen.2023.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Either deletion or co-deletion of chromosomal arms 1p or 19q is a characteristic and early genetic event in oligodendroglial tumors that is associated with a better prognosis and enhanced response to therapy. Information of 1p/19q status is now regarded as the standard of care when managing oligodendroglial tumors for therapeutic options in anticipation of the increased survival and progression-free survival times associated with it. Keeping this in view, we first time attempted to establish the FISH based detection of 1p/19q deletion in glioma tissue samples to evaluate its role and involvement in the disease.Method: Overall 39 glioma cases of different histologies were evaluated by fluorescence in situ hybridization (FISH) technique using specific FISH probes with Olympus BX43 fluorescent microscope to detect chromosomes 1p and 19q or co-deletions therein.Results: Of the 39 glioma samples, overall 27 (69.2%) were found to have deletion either in 1p, 19q or both. Deletions were observed in 23.0%, 7.6% and 38.4% in 1p, 19q and 1p/19q co-deletions respectively. Overall oligidendrioglioma presented with 53.8% (21 of 39) deletions, astrocytoma group showed 12.8% and GBM accounted for 2.5% deletions. Overall survival and disease free survival was seen significantly better in oligidendrioglioma and astrocytoma with deleted tumors as compared to non-deleted ones (p<0.05).Conclusion: Allelic losses on 1p and 19q, either discretely or shared, were more frequent in classic oligodendrogliomas than in either astrocytoma or Glioblastoma with better survival and response to therapy.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 35 条
  • [1] Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study
    Ahluwalia, Manmeet S.
    Xie, Hao
    Dahiya, Saurabh
    Hashemi-Sadraei, Nooshin
    Schiff, David
    Fisher, Paul G.
    Chamberlain, Marc C.
    Pannullo, Susan
    Newton, Herbert B.
    Brewer, Cathy
    Wood, Laura
    Prayson, Richard
    Elson, Paul
    Peereboom, David M.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2015, 122 (01) : 111 - 119
  • [2] Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
    Bauman, GS
    Ino, Y
    Ueki, K
    Zlatescu, MC
    Fisher, BJ
    Macdonald, DR
    Stitt, L
    Louis, DN
    Cairncross, JG
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (03): : 825 - 830
  • [3] Biology of oligodendrocyte and myelin in the mammalian central nervous system
    Baumann, N
    Pham-Dinh, D
    [J]. PHYSIOLOGICAL REVIEWS, 2001, 81 (02) : 871 - 927
  • [4] Diagnosis and treatment of recurrent high-grade astrocytoma
    Butowski, NA
    Sneed, PK
    Chang, SM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (08) : 1273 - 1280
  • [5] Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
    Cairncross, Gregory
    Berkey, Brian
    Shaw, Edward
    Jenkins, Robert
    Scheithauer, Bernd
    Brachman, David
    Buckner, Jan
    Fink, Karen
    Souhami, Luis
    Laperierre, Normand
    Mehta, Minesh
    Curran, Walter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2707 - 2714
  • [6] Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
    Cairncross, Gregory
    Wang, Meihua
    Shaw, Edward
    Jenkins, Robert
    Brachman, David
    Buckner, Jan
    Fink, Karen
    Souhami, Luis
    Laperriere, Normand
    Curran, Walter
    Mehta, Minesh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) : 337 - 343
  • [7] Gliomas With 1p/19q Codeletion: a.k.a. Oligodendroglioma
    Cairncross, Gregory
    Jenkins, Robert
    [J]. CANCER JOURNAL, 2008, 14 (06) : 352 - 357
  • [8] Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
    Cairncross, JG
    Ueki, K
    Zlatescu, MC
    Lisle, DK
    Finkelstein, DM
    Hammond, RR
    Silver, JS
    Stark, PC
    Macdonald, DR
    Ino, Y
    Ramsay, DA
    Louis, DN
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) : 1473 - 1479
  • [9] Prediagnostic Plasma IgE Levels and Risk of Adult Glioma in Four Prospective Cohort Studies
    Calboli, Federico C. F.
    Cox, David G.
    Buring, Julie E.
    Gaziano, J. Michael
    Ma, Jing
    Stampfer, Meir
    Willett, Walter C.
    Tworoger, Shelley S.
    Hunter, David J.
    Camargo, Carlos A., Jr.
    Michaud, Dominique S.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (21) : 1588 - 1595
  • [10] Clarke J, 2010, ARCH NEUROL-CHICAGO, V67, P279, DOI 10.1001/archneurol.2010.5